Your browser doesn't support javascript.
Evidence of SARS-CoV-2 reinfection: analysis of 35,000 subjects and overview of systematic reviews.
Pecoraro, Valentina; Pirotti, Tommaso; Trenti, Tommaso.
  • Pecoraro V; Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, Italy. v.pecoraro@ausl.mo.it.
  • Pirotti T; Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, Italy.
  • Trenti T; Department of Laboratory Medicine and Pathology, Azienda USL of Modena, Modena, Italy.
Clin Exp Med ; 2022 Oct 26.
Article in English | MEDLINE | ID: covidwho-2085405
ABSTRACT

BACKGROUND:

Reinfection by SARS-CoV-2 is a rare but possible event. We evaluated the prevalence of reinfections in the Province of Modena and performed an overview of systematic reviews to summarize the current knowledge.

METHODS:

We applied big data analysis and retrospectively analysed the results of oro- or naso-pharyngeal swab results tested for molecular research of viral RNA of SARS-CoV-2 between 1 January 2021 and 30 June 2021 at a single center. We selected individuals with samples sequence of positive, negative and then positive results. Between first and second positive result we considered a time interval of 90 days to be sure of a reinfection. We also performed a search for and evaluation of systematic reviews reporting SARS-CoV-2 reinfection rates. Main information was collected and the methodological quality of each review was assessed, according to A Measurement Tool to Assess systematic Reviews (AMSTAR).

RESULTS:

Initial positive results were revealed in more than 35,000 (20%) subjects; most (28%) were aged 30-49 years old. Reinfection was reported in 1,258 (3.5%); most (33%) were aged 30-49 years old. Reinfection rates according to vaccinated or non-vaccinated subjects were 0.6% vs 1.1% (p < 0.0001). Nine systematic reviews were identified and confirmed that SARS-CoV-2 reinfection rate is a rare event. AMSTAR revealed very low-moderate levels of quality among selected systematic reviews.

CONCLUSIONS:

There is a real, albeit rare risk of SARS-CoV-2 reinfection. Big data analysis enabled accurate estimates of the reinfection rates. Nevertheless, a standardized approach to identify and report reinfection cases should be developed.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S10238-022-00922-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S10238-022-00922-0